| Product Includes | Product # | Quantity | Mol. Wt | Isotype/Source |
|---|---|---|---|---|
| MLKL (D6W1K) Rabbit mAb | 37705 | 20 µl | 54 kDa | Rabbit IgG |
| Phospho-MLKL (Ser345) (D6E3G) Rabbit mAb | 37333 | 20 µl | 54 kDa | Rabbit IgG |
| Caspase-3 (D3R6Y) Rabbit mAb | 14220 | 20 µl | 35, 19, 17 kDa | Rabbit IgG |
| Phospho-RIP3 (Thr231/Ser232) (E7S1R) Rabbit mAb | 91702 | 20 µl | 46-62 kDa | Rabbit IgG |
| Gasdermin D (E9S1X) Rabbit mAb | 39754 | 20 µl | 53, 30 kDa | Rabbit IgG |
| Cleaved Gasdermin D (Asp276) (E3E3P) Rabbit mAb | 10137 | 20 µl | 31 kDa | Rabbit IgG |
| IL-1β (D3H1Z) Rabbit mAb | 12507 | 20 µl | 17,31 kDa | Rabbit IgG |
| Cleaved-IL-1β (Asp117) (E7V2A) Rabbit mAb | 63124 | 20 µl | 17 kDa | Rabbit IgG |
| RIP3 (D4G2A) Rabbit mAb | 95702 | 20 µl | 46-62 kDa | Rabbit IgG |
| Anti-rabbit IgG, HRP-linked Antibody | 7074 | 100 µl | Goat |
Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.
Description
The Mouse Reactive PANoptosis Antibody Sampler Kit provides an economical means of detecting the activation of PANoptosis in mouse samples. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Storage
Background
Programmed cell death (PCD) plays important roles in organismal development and immune responses. There are three major PCD pathways: apoptosis, pyroptosis, and necroptosis. Apoptosis is a non-inflammatory cell death and is characterized by a series of proteolytic cleavage, beginning with the initiator caspases (caspases-8/9), then the executioner caspases (caspases-3/6/7), followed by cleavage of substrate proteins to drive apoptotic cell death (1,2). During pyroptosis, caspase-1 is proteolytically activated through a protein complex called inflammasome, then the activated caspase-1 can cleave Gasdermin D (GSDMD), IL-1β, and IL-18. The freed GSDMD N-terminal domains from the cleavage form pores in the plasma membrane to drive pyroptotic cell lysis and release of the cleaved and matured IL-1β and IL-18, as well as damage-associated molecular patterns (DAMPs) (3,4). The key steps in necroptosis include the receptor-interacting protein kinase 3 (RIPK3)-dependent phosphorylation of mixed lineage kinase domain-like protein (MLKL), translocation of phosphorylated MLKL to plasma membrane, and disruption of plasma membrane integrity (5,6). In contrast to the non-inflammatory nature of apoptosis, both pyroptosis and necroptosis are proinflammatory (7). While early studies of these PCD pathways focused on their distinct individual features and underlying mechanisms, recent findings point to crosstalk and redundancies among these processes under certain conditions, where the three pathways are activated, not independently of each other, and compensatory responses occur when one pathway is blocked. This new form of PCD with key features of pyroptosis, apoptosis, and/or necroptosis has been termed PANoptosis (8,9). PANoptosis is a coordinated cell death pathway driven by a cytoplasmic protein complex named the PANoptosome, whose components provide scaffold and catalytic functions to engage pyroptosis, apoptosis, and/or necroptosis (10,11).
- Hengartner, M.O. (2000) Nature 407, 770-6.
- Zimmermann, K.C. et al. (2001) Pharmacol Ther 92, 57-70.
- Shi, J. et al. (2017) Trends Biochem Sci 42, 245-254.
- Rathinam, V.A.K. and Chan, F.K. (2018) Trends Mol Med 24, 304-318.
- Christofferson, D.E. and Yuan, J. (2010) Curr Opin Cell Biol 22, 263-8.
- Vandenabeele, P. et al. (2010) Nat Rev Mol Cell Biol 11, 700-14.
- Nozaki, K. et al. (2022) Annu Rev Immunol 40, 469-498.
- Malireddi, R.K.S. et al. (2019) Front Cell Infect Microbiol 9, 406.
- Zheng, M. and Kanneganti, T.D. (2020) Immunol Rev 297, 26-38.
- Christgen, S. et al. (2020) Front Cell Infect Microbiol 10, 237.
- Samir, P. et al. (2020) Front Cell Infect Microbiol 10, 238.
Background References
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.